[article] 
inJournal of Autism and Developmental Disorders > 48-9 (September 2018) . - p.2968-2979

Titre :	Cost-Effectiveness of Universal or High-Risk Screening Compared to Surveillance Monitoring in Autism Spectrum Disorder
Type de document :	texte imprimé
Auteurs :	T. YUEN, Auteur ; M.T. CARTER, Auteur ; P. SZATMARI, Auteur ; Wendy J. UNGAR, Auteur
Article en page(s) :	p.2968-2979
Langues :	Anglais (eng)
Mots-clés :	Autism spectrum disorder  Cost-effectiveness analysis  Health services research  Screening
Index. décimale :	PER Périodiques
Résumé :	The American Academy of Pediatrics recommends universal screening for autism spectrum disorder at 18 and 24 months. This study compared the cost-effectiveness of universal or high-risk screening to surveillance monitoring. Simulation models estimated the costs and outcomes from birth to age 6 years. The incremental cost per child diagnosed by 36 months was $41,651.6 for high-risk screening and $757,116.9 for universal screening from the societal perspective. Universal screening may not be a cost-effective approach to increase earlier treatment initiation, as most children initiated treatment after age 60 months. Eliminating wait times resulted in more children initiated treatment by 48 months, but at a high initial cost that may be offset by future cost-savings related to better outcomes.
En ligne :	http://dx.doi.org/10.1007/s10803-018-3571-4
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=367

[article] Cost-Effectiveness of Universal or High-Risk Screening Compared to Surveillance Monitoring in Autism Spectrum Disorder [texte imprimé] / T. YUEN, Auteur ; M.T. CARTER, Auteur ; P. SZATMARI, Auteur ; Wendy J. UNGAR, Auteur . - p.2968-2979.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 48-9 (September 2018) . - p.2968-2979

Mots-clés :	Autism spectrum disorder  Cost-effectiveness analysis  Health services research  Screening
Index. décimale :	PER Périodiques
Résumé :	The American Academy of Pediatrics recommends universal screening for autism spectrum disorder at 18 and 24 months. This study compared the cost-effectiveness of universal or high-risk screening to surveillance monitoring. Simulation models estimated the costs and outcomes from birth to age 6 years. The incremental cost per child diagnosed by 36 months was $41,651.6 for high-risk screening and $757,116.9 for universal screening from the societal perspective. Universal screening may not be a cost-effective approach to increase earlier treatment initiation, as most children initiated treatment after age 60 months. Eliminating wait times resulted in more children initiated treatment by 48 months, but at a high initial cost that may be offset by future cost-savings related to better outcomes.
En ligne :	http://dx.doi.org/10.1007/s10803-018-3571-4
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=367